12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SCV-07: Development discontinued

SciClone discontinued development of SCV-07 to prevent OM after a pre-planned interim analysis of 85 evaluable patients with head and neck cancer receiving concurrent chemoradiation in a double-blind, U.S. Phase IIb trial showed that the compound would not meet the pre-specified efficacy endpoints vs. placebo. The primary endpoint of the trial was the change from baseline in the proportion of patients with clinically assessed ulcerative OM, defined as...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >